Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.40 |
| ▸ | LPL | P06858 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 10/20 | 0.40 |
| ▸ | ACACA | Q13085 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882012 | 1.00 | LIPG (0.40) | LIPGLPLACACBACACAALDH1A1 | |
| SCHEMBL27181083 | 0.89 | ALDH1A1 (0.40) | LIPGLPLALDH1A1P4HB | |
| SCHEMBL5113464 | 0.89 | ALDH1A1 (0.40) | LIPGLPLALDH1A1P4HB | |
| SCHEMBL14014450 | 0.83 | AAK1 (0.48) | LIPGLPL | |
| SCHEMBL5106944 | 0.83 | AAK1 (0.48) | LIPGLPL | |
| SCHEMBL12020859 | 0.83 | AAK1 (0.48) | LIPGLPL | |
| SCHEMBL29723680 | 0.83 | LIPG (0.41) | LIPGLPLACACBALDH1A1 | |
| SCHEMBL5106947 | 0.83 | AAK1 (0.48) | LIPGLPL | |
| SCHEMBL1658478 | 0.79 | PTGS1 (0.48) | LIPGLPLALDH1A1P4HB | |
| SCHEMBL18241160 | 0.78 | PTGS1 (0.50) | LIPGLPLP4HBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557211-B2 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20060128741-A1 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| WO-2006053166-A1 | 8H-IMIDAZO[4,5-D]THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128741-A1 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, CYP4B1 | LIPG 4299/4885LPL 3671/4885ACACB 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.